Arvinas (NASDAQ:ARVN) Earns Hold Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Arvinas (NASDAQ:ARVNGet Rating) in a research report sent to investors on Tuesday morning, Briefing.com reports. The brokerage issued a hold rating and a $42.00 price target on the stock. Jefferies Financial Group also issued estimates for Arvinas’ Q2 2022 earnings at ($1.03) EPS, Q3 2022 earnings at $0.28 EPS, Q4 2022 earnings at ($0.58) EPS, FY2022 earnings at ($2.52) EPS, FY2023 earnings at ($0.44) EPS, FY2024 earnings at ($4.04) EPS, FY2025 earnings at ($3.46) EPS and FY2026 earnings at ($1.98) EPS.

A number of other analysts have also recently weighed in on ARVN. Piper Sandler reduced their price objective on shares of Arvinas from $116.00 to $76.00 and set an overweight rating for the company in a research note on Monday, May 23rd. Citigroup reduced their price objective on shares of Arvinas to $103.00 and set a buy rating for the company in a research note on Friday, May 20th. Stifel Nicolaus cut their target price on shares of Arvinas from $93.00 to $85.00 in a research note on Tuesday, April 26th. Cantor Fitzgerald reiterated an overweight rating on shares of Arvinas in a research note on Friday, April 1st. Finally, Morgan Stanley began coverage on shares of Arvinas in a research note on Wednesday, April 6th. They set an equal weight rating and a $65.00 target price for the company. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $96.88.

ARVN stock opened at $42.42 on Tuesday. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -10.17 and a beta of 2.07. Arvinas has a 12 month low of $34.90 and a 12 month high of $108.46. The firm has a 50 day moving average of $46.96 and a two-hundred day moving average of $61.91.

Arvinas (NASDAQ:ARVNGet Rating) last posted its earnings results on Thursday, May 5th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.29). Arvinas had a negative return on equity of 29.38% and a negative net margin of 326.72%. The business had revenue of $24.20 million during the quarter, compared to the consensus estimate of $25.51 million. Arvinas’s revenue for the quarter was up 340.0% compared to the same quarter last year. As a group, sell-side analysts expect that Arvinas will post -4.36 earnings per share for the current fiscal year.

In other Arvinas news, Director Briggs Morrison sold 20,960 shares of the stock in a transaction dated Thursday, April 14th. The shares were sold at an average price of $66.44, for a total transaction of $1,392,582.40. Following the sale, the director now owns 19,976 shares of the company’s stock, valued at approximately $1,327,205.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.78% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in ARVN. Dimensional Fund Advisors LP lifted its position in Arvinas by 37.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 135,230 shares of the company’s stock valued at $11,114,000 after purchasing an additional 36,927 shares during the period. Guggenheim Capital LLC acquired a new stake in shares of Arvinas in the 3rd quarter valued at approximately $213,000. Wellington Management Group LLP raised its position in shares of Arvinas by 3.5% in the 3rd quarter. Wellington Management Group LLP now owns 596,664 shares of the company’s stock valued at $49,034,000 after acquiring an additional 20,351 shares during the period. Voloridge Investment Management LLC acquired a new stake in shares of Arvinas in the 3rd quarter valued at approximately $2,549,000. Finally, UBS Group AG raised its position in shares of Arvinas by 117.2% in the 3rd quarter. UBS Group AG now owns 143,198 shares of the company’s stock valued at $11,768,000 after acquiring an additional 77,270 shares during the period. Institutional investors own 84.52% of the company’s stock.

About Arvinas (Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Featured Articles

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.